Asterisk Lifesciences Ltd

Directors' report and financial statements

for the year ended 31 March 2016

Company information

Directors

Narsimha Shibroor Kamath Gautam Rasiklal Ashra

Company number

9304650

Registered office

350 Kilburn Lane

London W9 3EF

Accountants

Farooq & Co (London) Ltd

350 Kilburn Lane

London W9 3Ef

Bankers

Barclays Bank plc Building 315 Heathrow Airport Hounslow, Middlesex

TW6 2JJ

Contents

	Page
Directors' report	1
Accountants' report	2
Profit and loss account	3
Balance sheet	4 - 5
Notes to the financial statements	6

Directors' report for the year ended 31 March 2016

The directors present their report and the financial statements for the year ended 31 March 2016.

Directors

The directors who served during the year are as stated below:

Narsimha Shibroor Kamath Gautam Rasiklal Ashra

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

This report was approved by the Board on 3 August 2016, and signed on its behalf by:

Narsimha Shibroor Kamath

Director

Profit and loss account for the year ended 31 March 2016

		2016	2015
	Notes	£	£
Turnover	2	838,788	· _
Cost of sales		(830,681)	-
Gross profit		8,107	-
Administrative expenses	•	(2,127)	(1,286)
Profit/(loss) on ordinary activities before taxation		5,980	(1,286)
Tax on profit/(loss) on ordinary	activities 3	(939)	-
Profit/(loss) for the year	8	5,041	(1,286)
Accumulated (loss)/profit broug	ht forward	(1,286)	-
Retained profit/(loss) carried	Corward	3,755	(1,286)

Balance sheet as at 31 March 2016

		2016		2015	
	Notes	£	£	£	£
Investments	4		684,560		-
Current assets					
Debtors	5	154,228		-	
Cash at bank and in hand		18,372		19,659	
		172,600		19,659	
Creditors: amounts falling		*			
due within one year	6	(853,305)		(20,845)	
Net current liabilities		·	(680,705)	- x	(1,186)
Total assets less current					
liabilities			3,855		(1,186)
Net assets/(liabilities)			3,855		(1,186)
Capital and reserves					
Called up share capital	7		100		100
Profit and loss account	8		3,755		(1,286)
					7
Shareholders' funds			3,855		(1,186)

The directors' statements required by Sections 475(2) and (3) are shown on the following page which forms part of this Balance Sheet.

Balance sheet (continued)

Directors' statements required by Sections 475(2) and (3) for the year ended 31 March 2016

For the year ended 31 March 2016 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and with the Financial Reporting Standard for Smaller Entities (effective April 2008).

These accounts were approved by the directors on 3 August 2016, and are signed on their behalf by:

Narsimha Shibroor Kamath

Director

Registration number 9304650

Gautam Rasiklal Ashra Director

Notes to the financial statements for the year ended 31 March 2016

 continued
COMMINGO

5.	Debtors	2016 £	2015 £
	Amounts owed by group undertakings	154,228	×
6.	Creditors: amounts falling due	2016	2015
	within one year	£	£
	Amounts owed to group undertaking Corporation tax	850,566 939	19,885
	Accruals and deferred income	1,800	960
		853,305	20,845
7.	Share capital	2016 £	2015 £
	Allotted, called up and fully paid	a.	a.
	100 Ordinary shares of £1 each	100	100
	Equity Shares		
	100 Ordinary shares of £1 each		100
8.	Reserves	Profit and loss	
		£	Total £
	At 1 April 2015	(1,286)	(1,286)
	Profit for the year	5,041	5,041
	At 31 March 2016	3,755	3,755

Notes to the financial statements for the year ended 31 March 2016

..... continued

9. Related party transactions

The company has sold products amounting to £838,788 during the year (2015: Nil) to its wholly owned subsidiary Asterisk Lifesciences (Ghana) Ltd, a company incorporated in Ghana.

The company has purchased products amounting to £830,681 during the year (2015: Nil) from its holding company, Bliss GVS Pharma Ltd.

The company owed £850,566 at the year end (2015: Nil) to its holding company, Bliss GVS Pharma Ltd (2015: £19,885).

The company was owed £154,228 at the year end (2015: Nil) by its subsidiary, Asterisk Lifesciences (Ghana) Ltd.

10. Controlling interest

The company is wholly owned by Bliss GVS Pharma Ltd incorporated in India. The directors of the company are also directors of the holding company.

The following pages do not form part of the statutory accounts.

Detailed trading profit and loss account and expenses schedule for the year ended 31 March 2016

	2016		2015	
	£	£	£	£
Sales				
Sales		838,788		-
		838,788		
Cost of sales				
Purchases	830,681		-	
	,	(830,681)	1	-
Gross profit	1%	8,107	-%	-
Administrative expenses				
Accountancy	1,800		960	
Bank charges	327		26	
General expenses	-		300	
	-	2,127		1,286
Operating profit/(loss)	1%	5,980	-%	(1,286)